Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | VEGFA | P15692 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27227543 | 0.85 | VEGFA (0.42) | MAPTNPC1RAB9AMAPK1TBK1 | |
| SCHEMBL30802301 | 0.85 | MAPT (0.43) | MAPTMAPK1POLBTBK1GPR119 | |
| SCHEMBL27226398 | 0.85 | MAPT (0.43) | MAPTMAPK1POLBTBK1GPR119 | |
| SCHEMBL13600192 | 0.85 | POLB (0.47) | MAPTPOLBTBK1GPR119VEGFA | |
| SCHEMBL29324395 | 0.84 | AKT1 (0.49) | MAPTNPC1RAB9ANFKB1MAPK1 | |
| SCHEMBL30802459 | 0.84 | AKT1 (0.49) | MAPTNPC1RAB9ANFKB1MAPK1 | |
| SCHEMBL30802461 | 0.84 | JAK2 (0.44) | MAPTTBK1ALDH1A1MGLLSMN1; SMN2 | |
| SCHEMBL27225984 | 0.84 | JAK2 (0.44) | MAPTTBK1ALDH1A1MGLLSMN1; SMN2 | |
| SCHEMBL13607277 | 0.82 | GPR119 (0.50) | MAPTNPC1RAB9ANFKB1MAPK1 | |
| SCHEMBL27227315 | 0.81 | TBK1 (0.46) | MAPTTBK1GPR119KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4594318-A1 | AKT1 MODULATORS | Alterome Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250092040-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-03-20 | — | — | US | disclosed |
| US-20240239797-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240239797-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-11999730-B1 | AKT1 modulators | ALTEROME THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240174667-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2024102621-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024073371-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024054512-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| US-7638531-B2 | Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-7638531-B2 | Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-20070167435-A1 | Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| US-20070167435-A1 | Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239797-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | MAPT 1885/4885NPC1 1743/4885RAB9A 1160/4885 |
| US-20070167435-A1 | Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists | HRH4, HRH3, HRH2 | MAPT 2125/4885NPC1 1270/4885RAB9A 3116/4885 |
| US-20250092040-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | MAPT 1885/4885NPC1 1743/4885RAB9A 1160/4885 |
| US-11999730-B1 | AKT1 modulators | AKT1S1, AKT1, AKT2 | MAPT 1885/4885NPC1 1743/4885RAB9A 1160/4885 |
| US-20240174667-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | MAPT 1885/4885NPC1 1743/4885RAB9A 1160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.